Compare LOAN & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOAN | BDSX |
|---|---|---|
| Founded | 1989 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Precision Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.3M | 122.0M |
| IPO Year | 1999 | 2020 |
| Metric | LOAN | BDSX |
|---|---|---|
| Price | $4.33 | $17.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 20.7K | ★ 153.6K |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | ★ 10.19% | N/A |
| EPS Growth | ★ 2.08 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | $9,688,641.00 | ★ $88,499,000.00 |
| Revenue This Year | N/A | $23.35 |
| Revenue Next Year | $4.47 | $19.33 |
| P/E Ratio | $12.34 | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $4.24 | $0.25 |
| 52 Week High | $6.05 | $20.21 |
| Indicator | LOAN | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 38.81 | 62.47 |
| Support Level | $4.29 | $6.33 |
| Resistance Level | $4.59 | N/A |
| Average True Range (ATR) | 0.08 | 1.84 |
| MACD | 0.00 | 0.20 |
| Stochastic Oscillator | 25.96 | 65.98 |
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.